Silver Book Fact

Cost-effectiveness of TAVR in sSAS patients

Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY gained and $43,114 per life-year (LY) gained.

Reynolds M, Lei Y, Wang K, Chinnakondepalli K, et al. Cost-Effectiveness of Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement. JACC. 2016; 67(1): 29-38. http://www.onlinejacc.org/content/67/1/29

Reference

Title
Cost-Effectiveness of Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement
Publication
JACC
Publication Date
2016
Authors
Reynolds M, Lei Y, Wang K, Chinnakondepalli K, et al.
Volume & Issue
Volume 67, Issue 1
Pages
29-38
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Disease specific status and generic health status improvements from TAVR and SAVR
    Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to…  
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
  • Improvements in QoL from TAVR in SAS patients
    Symptomatic aortic stenosis (SAS) patients who underwent transcatheter aortic valve replacement (TAVR) experienced quality of life (QoL) improvements from 5.3 at baseline (10 point scale with 10=best imaginable health state)…  
  • From approval in 2011 through 2015 >54,000 TAVRs were performed in 418 centers in 48 states
     
  • TAVR improves quality of life in SAS patients